BPK Bespak

TIDMCSRT

RNS Number : 2127E

Consort Medical PLC

02 November 2015

Consort Medical plc

2 November 2015

Notification of Change of Auditor

Consort Medical plc ('the Company') announces its intention to appoint KPMG LLP as auditor of the Company. The Company first reported its intention to hold a competitive audit tender process in its annual report & financial statements 2014-15. This was initiated in light of emerging best practice and the fact that the existing auditor, PWC had been incumbent for some time. A rigorous tender process was conducted, which resulted in the Consort Medical plc Board recommending that KPMG LLP be appointed as auditor of the Company with effect from the 2015-16 financial year. The appointment will be put to shareholders for approval at the next general meeting.

Accordingly, the Company announces that a statement of reasons ('The Statement') from PWC, confirming its resignation as the Company's auditor as a result of tender process, was received by the Company on 28 October 2015 in accordance with Section 519 of The Companies Act 2006. Copies of The Statement received and the covering letter have been submitted to The National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM.

Enquiries:

 
 Consort Medical                             Tel: +44 1442 867 
  Jonathan Glenn - Chief Executive Officer    920 
  Richard Cotton - Chief Financial Officer 
 
   FTI Consulting                              Tel: +44 203 727 
   Ben Atwell/ Simon Conway                    1000 
 
 

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Our businesses

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). To learn more about our company visit our website at www.consortmedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPKBDNBBDDADK

(END) Dow Jones Newswires

November 02, 2015 07:41 ET (12:41 GMT)

Bespak (LSE:BPK)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024

Bespak (LSE:BPK)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024